Tigress Financial Maintains Buy on Medline, Raises Price Target to $60
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Tigress Financial analyst Ivan Feinseth maintains Medline (NASDAQ:MDLN) with a Buy and raises the price target from $55 to $60.
Tigress Financial analyst Ivan Feinseth maintains Medline (NASDAQ:MDLN) with a Buy and raises the price target from $55 to $60.